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B.C.G. TREATMENT OF PLEURAL
AND PERITONEAL TUMOUR
GROWTH IN RATS. M. V. PIMM.
Cancer Research Campaign Laboratories,
University of Nottingham.
Growth of intrapleurally injected cells of
immunogenic 3-methylcholanthrene induced
rat sarcomata was suppressed by intrapleural
injection of viable or radiation sterilized
B.C.G. organisms. As little as 10 ,tg of
B.C.G. was effective and treatment was
successful even if given several days after
tumour challenge. B.C.G. administered in-
travenously or subcutaneously was without
influence on pleural tumour growth. Simi-
larly, peritoneal growth of these sarcomata
was suppressed only by the intraperitoneal
injections of B.C.G. organisms.
In contrast, pleural or peritoneal growths
from cells of other rat tumours, which lacked
significant immunogenicity, were not con-
trolled by this type of B.C.G. treatment.
Nevertheless, these studies indicate the
potential of B.C.G. (contact) immunotherapy
for treatment of thoracic and peritoneal
tumour deposits, which might perhaps have
a clinical application, for example in the
treatment of malignant mesothelioma of the
pleura and peritoneum.
DETECTION OF TUMOUR ASSO-
CIATED EMBRYONIC ANTIGENS.
M. R. PRICE atid R. C. REES. Cancer
Research Campaign Laboratories, University
of Nottingham.
Chemically induced and spontaneously
arising rat tumours express embryonic anti-
gens, which are also demonstrable on embryo
cells taken between 14 and 16 days of
gestation. The expression of tumour asso-
ciated embryonic antigens may be a common
feature of malignant transformation since
these antigens are present on tumours which
lack demonstrable levels of tumour specific
rejection antigens. Also, unlike the tumour
rejection antigens associated with chemically
induced tumours, they show cross-reactivity,
especially between tumours of the same
histological type. This suggests that the
tumour associated embryonic antigens, which
differ from other embryonic products such as
cx-foetoprotein in being immunogenic in the
autochthonous host, may be appropriate
markers for immunodiagnostic assays. This
is further emphasized by studies to be dis-
cussed, showing that homogeneous prepara-
tions of soluble embryonic antigen can be
isolated readily from tumour cytoplasmic
fractions, indicating the possibility ofutilizing
defined reagents in immunoassays for moni-
toring circulating tumour antigen.
CORRELATION OF SERUM LEVELS
OF HEPATOMA D23 ANTIGEN, ANTI-
BODY AND IMMUNE COMPLEXES
WITH GROWTH OF TRANSPLANTED
TUMOURS. M. R. PRICE and J. G.
BOWEN. Cancer Research Campaign Labora-
tories, University of Nottingham.
Hepatoma D23 antigen has been moni-
tored in the serum of tumour bearing rats
using an antibody inhibition assay based
upon membrane immunofluorescence methods
for detecting antibody in tumour immune
sera. Simultaneously, levels of tumour
specific antibody in sera of tumour bearing
rats were analysed by their direct membrane
immunofluorescence staining with hepatoma
D23 cells. Applying these techniques, it has
been established that during the early stages
of subcutaneous growth of hepatoma D23 in
syngeneic rats there is significant shedding of
tumour specific antigen into the circulation.
This is then depressed after a period of
between 10 and 14 days tumour growth, at
which time circulating tumour specific im-
mune complexes are detectable. Finally,
antibody can be detected. These observa-
tions are relevant to current views that cell
mediated immunity to tumour cells can be
blocked by interaction ofantibody or immune
complexes with tumour cells or by antigen
inhibition of effector cells. Furthermore,
these model studies indicate the importance
of designing immunochemical assays for
diagnostic and prognostic purposes during
tumour therapy.
THE GROWTH OF SPONTANEOUS
MELANOMA ALLOGRAFTS IN
IMMUNOSUPPRESSED NEONATAL
DOGS. G. R. BETTON and L. N. OWEN.
Department ofAnimal Pathology, University
of Cambridge.
Clinical cases ofmelanoma in the dog have
provided tumour cells for transplantation as
fresh cell suspensions, cells stored in a frozen
state and tissue culture cell lines. Tumour
growth has been achieved in 18 of 36 cases
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